Publication:
The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia

Simple item page
dc.contributor.authorŞEKERCİ, ÇAĞRI AKIN
dc.contributor.authorsTop, Tuncay; Sekerci, Cagri Akin; Isbilen-Basok, Banu; Tanidir, Yiloren; Tinay, Ilker; Isman, Ferruh Kemal; Akbal, Cem; Simsek, Ferruh; Tarcan, Tufan
dc.date.accessioned2022-03-12T22:23:46Z
dc.date.available2022-03-12T22:23:46Z
dc.date.issued2017
dc.description.abstractAimsThe aim of this study was to determine the value of urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF-Beta-1), tissue inhibitor of matrix metalloproteinase 2 (TIMP-2) levels to predict the urodynamic profile before and after botulinum neurotoxin type A (BoNT-A) treatment in children with myelodysplasia. MethodsThis prospective study included 15 children with myelodysplasia who underwent intradetrusor BoNT-A injections due to neurogenic detrusor overactivity (NDOA). Urine samples of each child were collected before and after BoNT-A injections, specifically at the first and third postoperative months. Urine samples were analyzed with ELISA method and NGF, TGF-Beta-1, and TIMP-2 levels were measured. Urine marker levels and clinical findings were assessed for statistical significance with Wilcoxon Signed Ranks Test and Friedman Test. ResultsA total of 15 children (5 boys and 10 girls) were assigned as the study group. Mean age of the patients was 7.12.5 years (range 2.5-11). A statistically significantly decline was observed in urinary TGF-Beta-1 and NGF levels following BoNT-A injections, compared to the preoperative levels (P<0.05). TIMP-2 levels also tend to decrease following BoNT-A injections but this was not statistically significant compared to the preoperative levels. ConclusionThis preliminary study, suggests urinary TGF-Beta-1 and NGF as a potent marker in children with NDOA, as they decline following BoNT-A injection. Further studies are needed in identifying their special role in assessing treatment success after invasive interventions.
dc.identifier.doi10.1002/nau.23207
dc.identifier.eissn1520-6777
dc.identifier.issn0733-2467
dc.identifier.pubmed28090659
dc.identifier.urihttps://hdl.handle.net/11424/234555
dc.identifier.wosWOS:000408229600031
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofNEUROUROLOGY AND URODYNAMICS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectnerve growth factor
dc.subjecttransforming growth factor beta 1
dc.subjecttissue inhibitor of matrix metalloproteinase 2
dc.subjectbotulinum neurotoxin type A
dc.subjectmyelodysplasia
dc.subjectNERVE GROWTH-FACTOR
dc.subjectBLADDER
dc.subjectOBSTRUCTION
dc.subjectINJECTIONS
dc.subjectFIBROSIS
dc.subjectTOXIN
dc.subjectSECONDARY
dc.titleThe effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia
dc.typearticle
dspace.entity.typePublication
local.avesis.idb821c853-3c6f-48a3-8a82-abf1b2c7c218
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages7
local.journal.quartileQ1
oaire.citation.endPage1902
oaire.citation.issue7
oaire.citation.startPage1896
oaire.citation.titleNEUROUROLOGY AND URODYNAMICS
oaire.citation.volume36
relation.isAuthorOfPublication1e489bdb-418e-4500-a522-6c0babb604b9
relation.isAuthorOfPublication.latestForDiscovery1e489bdb-418e-4500-a522-6c0babb604b9

Files

Collections

Research Outputs